Peripheral vascular devices and equipment are used to treat peripheral vascular diseases which are slow and progressive blood circulation disorders caused by blockages, narrowing, or spasms in blood vessels outside the heart and brain including arteries and veins. The main types of peripheral vascular devices and equipment are peripheral vascular stents, percutaneous transluminal angioplasty balloons, catheters, PTA guide wires, atherectomy devices, chronic total Occlusion devices, aortic stents, synthetic surgical grafts, embolic protection devices, and inferior vena cava filters. The catheter is a tubular medical device for insertion into canals, vessels, passageways, or body cavities to permit injection or withdrawal of fluids or to keep a passage open. The applications involved are the treatment of peripheral blood vessels damaged and the treatment of peripheral blood vessels blockage. The various end-users are hospital applications and clinic applications. The peripheral vascular devices and equipment market research report is one of a series of new reports from The Business Research Company that provides peripheral vascular devices and equipment market statistics, including peripheral vascular devices and equipment industry global market size, regional shares, competitors with a peripheral vascular devices and equipment market share, detailed peripheral vascular devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vascular devices and equipment industry. This peripheral vascular devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peripheral vascular devices and equipment market size will grow from $7.77 billion in 2022 to $8.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peripheral vascular devices and equipment market size is expected to grow to $10.04 billion in 2027 at a CAGR of 5.0%. The peripheral vascular devices and equipment market is driven by the rising number of people with peripheral artery diseases. Peripheral artery diseases are caused when arteries in the human body are blocked by plaque consisting of fats, cholesterol, and other substances restricting their blood flow to important organs. Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation. The disease is different in younger populations; but, the incidence rises sharply, with over 20% of people over 80 years old having PAD. According to the Center for Disease Control and Prevention (CDC), approximately 8.5 million people in the USA are suffering from peripheral artery diseases, of which 12-20% are aged above 60 years. Stringent approval processes, product recalls and failures act as a restraint to the peripheral vascular devices and equipment market. Product recalls and failures potentially affect the brand image of the companies within this market. According to the US Food and Drug Administration (FDA), a product recall is made to perform corrective actions or prevent hazardous effects to patients. For instance, in January 2022, Medtronic was instructed to recall its artery-clearing HawkOne System due to reported injuries. \ To reduce incidences associated with the peripheral devices and ensure that the devices are safe and have the least adverse reactions, FDA is restricting devices for use, sending field safety notices, and making product recall to correct the devices. These stringent approval processes and regulatory policies may impact the peripheral devices and equipment market. Bio-absorbable stents are gaining popularity in the peripheral vascular devices and equipment market to eliminate thrombogenic risk factors and enhance clinical applicability. Bio-absorbable stents are made of natural soluble materials that disappear after insertion and eliminate the risk of late stent thrombosis. They help in protecting the body from inflammation or reduced blood flow due to late-stent thrombosis (a condition where the stent used for treatment stays inside the body for a prolonged period). Companies in this market are increasing their focus on developing and commercializing bio-absorbable stents. For instance, in 2020, Boston Scientific is demanded to start its Synergy Megatron bioabsorbable polymer coronary stent system. It is intended for large proximal vessels, including over main, bifurcations, and ostial lesions. It is made in 3.5 mm to 5.0 mm diameters. It owns enhanced strength and the capacity to create tapered vessels. In January 2022, the U.S Food and Drug Administration issued notice to Medtronic plc for Class I medical device recall for its HawkOne System for clearing out clogged arteries. The notice was issue after certain instances of injuries were reported. In September 2021, Boston Scientific, a US-based manufacturer of medical devices acquired Devoro Medical, Inc for an undisclosed amount. This acquisition of devoro medical inc will add the WOLF platform and advances efforts to ensure physicians have the right tools to improve procedural efficiencies. Devoro Medical, Inc., is a US-based manufacturer of medical technology. Major players in the peripheral vascular devices and equipment market are Medtronic, Boston Scientific Corporation, Abbott, Cook group, Angiomed GmbH & Co., Medizintechnik KG, Terumo Corporation, ENDOLOGIX Inc., Bolton medical Inc., and JOTEC. North America was the largest region in global peripheral vascular devices and equipment market in 2022. Western Europe was the second-largest region in global peripheral vascular devices and equipment market. The regions covered in the peripheral vascular devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peripheral vascular devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, and Australia. The peripheral vascular devices and equipment market consist of sales of peripheral vascular stents, percutaneous transluminal angioplasty balloons, PTA drug-eluting balloons, embolic protection devices, inferior vena cava filters, Aortic stent-grafts, synthetic surgical drafts, and peripheral guide wires. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peripheral vascular devices and equipment market is segmented - 1) By Type: Peripheral vascular stents, Percutaneous transluminal angioplasty balloons, Catheters, PTA guide wires, Atherectomy devices, Chronic total acclusion devices, Aortic stents, Synthetic surgical grafts, Embolic protection devices, Inferior vena cava filters 2) By End User: Hospital applications, Clinic applications, 3) By Application: Treatment of Peripheral Blood Vessels Damaged, Treatment of Peripheral Blood Vessels Blockage

Interventional neurology devices and equipment are used to treat neurovascular diseases such as aneurysms, arteriovenous malformations, cavernous malformations, and stroke. The main types of interventional neurology devices and equipment are aneurysm coiling and embolization devices, cerebrospinal fluid management devices, neuro thrombectomy devices, and support devices. The neuro thrombectomy devices are used to perform mechanical thrombus removal from intracranial arteries angiographically. The aneurysm coiling and embolization devices types are embolic coils, flow diversion devices, and liquid embolic devices. The angioplasty devices types are carotid artery stents and embolic protection systems. The support devices types are micro guidewires and microcatheters. The neurothrombectomy device types are clot retrieval devices, suction and aspiration devices, and snares. The various end-users are hospitals, neurology clinics, ambulatory care centres, and others. The interventional neurology devices and equipment market research report is one of a series of new reports from The Business Research Company that provides interventional neurology devices and equipment market statistics, including interventional neurology devices and equipment industry global market size, regional shares, competitors with a interventional neurology devices and equipment market share, detailed interventional neurology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the interventional neurology devices and equipment industry. This interventional neurology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional neurology devices and equipment market size will grow from $1.99 billion in 2022 to $2.17 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional neurology devices and equipment market size is expected to grow to $2.97 billion in 2027 at a CAGR of 8.1%. An increase in the patient population with neurological disorders is driving the Interventional neurology devices market. Neural disorders like Alzheimer's disease, cerebrovascular diseases including stroke, migraine, and other headache disorders are on the rise. The rapid increase in the geriatric population, high-stress levels in young individuals, and head injuries due to accidents are the main reasons for neural disorders. For example, according to the Brain Aneurysm Foundation, it is estimated that in the United States, 6 million people suffer from unruptured brain aneurysms. Also, according to World Health Organization, more than 50 million have epilepsy and over 47 million have dementia. Hence, the rapid increase in the incidence of neurological disorders is slated to boost the market in the forecast period. Strict regulatory policies by the US FDA for the approval of Interventional Neurological Devices will hinder the interventional neurological devices market growth. FDA approves the devices based on the class of the devices. Most of the devices under Interventional Neurological Devices are classified under the class 3 devices. Class 3 devices are required to undergo a lot of approvals from the regulatory bodies which is a time-consuming process. For example, the approval for the class 3 devices may take more than 36 months, thereby increasing the overall cost of product development, impacting the market negatively. Stryker Inc.’s latest technological development Neuroform Atlas Stent System is expected to provide significant results to treat brain aneurysms with embolic coils. The introduction of such technologies would drive the interventional neurological device market in the future. The Atlas stent system provides great support during the coiling procedures and it has been designed s to provide the coil support and wall apposition needed to perform an effective stent-assisted coiling procedure. Neuroform Atlas has enhanced stent conformability, a low-profile delivery system, and high deployment accuracy even in distal anatomy making it the latest choice of the neuro-surgeons, thereby steering the market. The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) presides over the regulation and approval of medical devices in the USA. Within CDRH, the Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the central and peripheral nervous system (neurotechnologies), including neuro-interventional medical devices that are used in the treatment of stroke. Also, the division of Neurological and Physical Medicine Devices (DNPMD) serves as the primary point of review at the FDA for regulatory submissions involving medical device neurotechnologies. Although the process of approval is strenuous and the time taken is too long, the devices approved by FDA have had a major impact on the markets and the products approved by FDA are successful. FDA has been actively approving devices in the interventional neurosurgery device division which has boosted the market’s growth. For example, approval of Stryker’s Neuroform Atlas Stent System, De Novo clearance for Nerivio Migra, and Pipeline Flex embolization by Medtronic are the recent approvals made by FDA which enhances the market’s growth. Major players in the interventional neurology devices and equipment market are Medtronic, Stryker, Terumo Corporation, Penumbra, COVIDien, Abbott, Merit Medical Systems, Johnson & Johnson Services Inc., W. L. Gore & Associates, and Bayer AG. North America was the largest region in the global interventional neurology devices and equipment market in 2022. Asia-Pacific was the second-largest region in the interventional neurology devices and equipment market. The regions covered in the global interventional neurology devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional neurology devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The interventional neurology devices and equipment market consists of sales of instruments such as carotid artery stents, embolic protection systems, micro guide wires, and micro catheters. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional neurology devices and equipment market is segmented - 1) By Type: Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices 2) By End-User: Hospitals, Neurology clinics, Ambulatory care centers and others 3) Aneurysm Coiling & Embolization Devices By Type: Embolic coils, Flow diversion devices, Liquid embolic devices 4) Angioplasty Devices by Type: Carotid artery stents, Embolic protection systems 5) Support Devices By Type, Micro guide wires, Micro catheters 6) Neurothrombectomy Devices By Type: CLOT retrieval devices, Suction and aspiration devices, Snares

Interventional cardiology devices and equipment are used in interventional cardiology, a branch of medicine that deals with the catheter-based treatment of structural heart diseases. The main types of interventional cardiology devices and equipment are angioplasty balloons, angioplasty stents, catheters, plaque modification devices, and other interventional cardiology devices. The catheter is a tubular medical device for insertion into canals, vessels, passageways, or body cavities to permit injection or withdrawal of fluids or for keeping the passage open. The market is divided by age group into new-born (0-30 days), infant (31 days-1 year), children (1-18 years), and adult (18+ years). The various applications involved are hospitals, clinics, cardiac catheterization labs, and ambulatory surgical centres. The interventional cardiology devices and equipment market research report is one of a series of new reports from The Business Research Company that provides interventional cardiology devices and equipment market statistics, including interventional cardiology devices and equipment industry global market size, regional shares, competitors with a interventional cardiology devices and equipment market share, detailed interventional cardiology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the interventional cardiology devices and equipment industry. This interventional cardiology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional cardiology devices and equipment market size will grow from $12.6 billion in 2022 to $13.72 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional cardiology devices and equipment market size is expected to grow to $18.24 billion in 2027 at a CAGR of 7.4%. The interventional cardiology devices and equipment market is being driven by an increase in cardiovascular diseases. Cardiovascular diseases are health problems that are associated with the blood vessels, circulatory system as well as heart. The rise in cardiovascular diseases has led to a rise in healthcare expenditure in the medical equipment market which further drives the interventional cardiac devices and equipment market. According to an estimate by Centers for Disease Control and Prevention (CDC),, heart diseases caused 697,000 deaths in 2020. Further, according to an estimate by WHO, cardiovascular diseases are expected to account for 23.6 million deaths by 2030. The intervention cardiology devices and equipment market is being restrained by the high costs associated with the procurement and use of interventional cardiology devices. The interventional cardiology devices include drug-eluting stents, tiny mesh tubes coated with medicines, and pacemakers. For instance, according to a study, implantable heart devices like pacemakers and stents cost two to six times more in the US than in Germany and other European Union countries. Advancement in the technology of Interventional cardiology devices is one of the major trends in the market. Advanced devices cover technologically advanced imaging modalities such as Intravenous Ultrasound (IVUS), Fractional Flow Reserve (FFR), and Optical Coherence Tomography (OCT). For instance, according to a study published by the US CDC (Centers for Disease Control and Prevention), the treatment of cardiovascular diseases has changed substantially due to the introduction of new drug therapies and devices such as guidewires and stents which allow the patient to live quality and longer lives. According to The International Standard for Medical Device Manufacturers ISO 13485:2012, which sets standards regarding both product quality and compliance with governmental regulations, medical device manufacturing companies should follow all the strictest regulations. Companies earning this certification have consistently met both regulatory and customer requirements. Within the United States, regulations for medical devices are known as Current Good Manufacturing Practices (cGMP). The FDA’s Center for Devices and Radiological Health (CDRH) is responsible for certifying medical devices should meet appropriate standards before they are made available for patient use. Major players in the interventional cardiology devices and equipment market are GE Healthcare, Abbott Laboratories, Boston Scientific Corporation, Medtronic Inc., Johnson & Johnson, B. Braun Melsungen AG, Biosensors International Ltd., Novacam Technologies Inc., Cook Medical LLC., and Biotronik SE & Co. KG. North America was the largest region in the global interventional cardiology devices and equipment market in 2022. Western Europe was the second-largest region in the interventional cardiology devices and equipment market. The regions covered in the global interventional cardiology devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional cardiology devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The interventional cardiology devices and equipment market consists of sales of equipment with technologies such as vascular closure, atherectomy, intravascular ultrasound, fractional flow reserve, and optical coherence tomography (OCT) that are used for the treatment of interventional structural heart diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional cardiology devices and equipment market is segmented - 1) By Type: Angioplasty Balloons, Angioplasty Stents, Catheters, Plaque Modification Devices, Other Interventional Cardiology Devices 2) By Age Group: New-born (0-30 days), Infant (31 days-1 year), Children (1-18 years), Adult (18+ years) 3) By Application: Hospitals, Clinics, Cardiac Catheterization Labs, Ambulatory Surgical Centers

Bioabsorbable stents are tubes inserted into blood vessels to unblock passageways and dissolve in the body after a period of time. The main products of bioabsorbable stents are polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Bioresorbable stents (BRS) or vascular scaffolds are coronary stents that can fully dissolve in the body. It is also segmented by absorption rate into slow-absorption stents and fast-absorption that are used in various applications such as coronary artery diseases, and peripheral artery diseases. The bioabsorbable stents market research report is one of a series of new reports from The Business Research Company that provides bioabsorbable stents market statistics, including bioabsorbable stents industry global market size, regional shares, competitors with a bioabsorbable stents market share, detailed bioabsorbable stents market segments, market trends and opportunities, and any further data you may need to thrive in the bioabsorbable stents industry. This bioabsorbable stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bioabsorbable stents market grew from $0.31 billion in 2022 to $0.34 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bioabsorbable stents market is expected to grow from $0.49 billion in 2027 at a CAGR of 9.2%. Increasing cardiovascular diseases is a key factor driving the growth of the bioabsorbable stents market. Cardiovascular disorders are the leading cause of death across the world and 4 out of 5 cardiovascular deaths are caused by strokes and heart attacks. Moreover, one-third of such deaths occur prematurely in people under the age of 70. Bioresorbable stents are built primarily to reduce these risks of late complications, such as scaffold thrombosis or restenosis, that can happen when a conventional metal stent's rigid metal backbone remains permanently rooted in the diseased vessel. According to the American Heart Association, it is estimated that more than 23.6 million die due to cardiovascular diseases by 2030. Therefore, increasing cardiovascular diseases are expected to drive the growth of the bioabsorbable stents market. The risks associated with bioabsorbable stents restrain the growth of the market. The high risks with stents force companies to withdraw their devices from the market reducing the revenues from bioabsorbable stents. For instance, Abbott had to withdraw its product Absorb and Boston Scientific terminated their Renuvia scaffold development program as the devices showed a high risk of myocardial infarction and thrombosis. This was due to the non-uniform structure of the polymer used in the stents that makes the device susceptible to large deformation and causes flow disruption. The drug-eluting stent (DES) is gaining significant popularity in the bioabsorbable stents market. The drug-eluting stent (DES) device was designed to avoid the regeneration of tissue that would otherwise obstruct the artery and this was a new step forward in the treatment of peripheral artery disease. Boston Scientific launched its self-expanding drug-eluting stent (DES) peripheral artery disease (PAD) scheme which helped the company to expand its PAD portfolio. Major players in the bioabsorbable stents market are Abbott Laboratories, Reva Medical, Elixir Medical Corporation, Biotronik SE & Co. KG, Amaranth Medical Inc., Zorion Medical, Tepha, Inc., S3V Vascular Technologies, ICON Interventional Systems, and Arterius Limited. North America was the largest region in the bioabsorbable stents market in 2022. Western Europe was the second largest region in the global bioabsorbable stents market report. The regions covered in global bioabsorbable stents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bioabsorbable stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The bioabsorbable stents market consists of sales of polymer-based bioabsorbable stents and metal-based bioabsorbable stents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bioabsorbable stents market is segmented - 1) By Product Type: Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents 2) By Absorption Rate: Slow- absorption stents, Fast- absorption Stents 3) By Applications: Coronary Artery Diseases, Peripheral Artery Diseases

The vascular grafts are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process improves the blood flow by redirecting blood from one area of the body to another. The main products of the vascular graft are hemodialysis access graft, endovascular stent graft, peripheral vascular graft, and coronary artery bypass graft. Endovascular stent graft refers to the method of minimally invasive method that is used to treat an aortic aneurysm and is performed to know the presence of abdominal pain, symptoms for the disease, and also for the size of the aneurysm. The various raw materials are polyester grafts, ePTFE, polyurethane grafts, and biosynthetic grafts. The various applications of vascular graft are coronary artery disease, aneurysm, vascular occlusion, and renal failure that are used by end-users such as hospitals and ambulatory surgical centres. The vascular graft market research report is one of a series of new reports from The Business Research Company that provides vascular graft market statistics, including vascular graft industry global market size, regional shares, competitors with a vascular graft market share, detailed vascular graft market segments, market trends and opportunities, and any further data you may need to thrive in the vascular graft industry. This vascular graft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global vascular grafts market grew from $2.96 billion in 2022 to $3.21 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular grafts market is expected to grow from $4.37 billion in 2027 at a CAGR of 8.1%. The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association (AHA), the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market. The high cost of medical treatment and complications related to prosthetic grafts are expected to restrain global vascular grafts market growth. The cost of the CABG (coronary artery bypass graft) surgery is very high in western countries. For instance, in the US, the average cost of coronary artery bypass surgery is $40,000, which varies widely by region and facility. Moreover, several complications are associated with prosthetic grafts such as disruption of an infected anastomotic suture line due to rupture or pseudoaneurysm formation, sepsis, amputation, thromboembolism, chances of reinfection due to vascular grafts reconstruct, enteric fistulae, the spread of bacterial infection to other sites, and death. Thus, high treatment costs and complications related to prosthetic grafts are expected to restrain the market growth. Companies in the vascular graft market are increasingly investing in technological advances for the development of innovative vascular grafts, including customization of vascular grafts. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and they can be customized to meet the patient’s specific anatomical needs. In June 2020, LeMaitre Vascular, a US-based medical device company, acquired Artegraft for $90 million. The acquisition the company expected to extend its product line with Artegraft’s innovative products and better serve the customers’ needs. Artegraft is a New Jersey-based seller of vascular grafts. Major players in the vascular graft market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic PLC., Getinge, Terumo Medical Corporation, and Gore Medical. North America was the largest region in the vascular graft market in 2022. Western Europe was the second largest region in the global vascular graft market report. The regions covered in the global vascular graft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vascular graft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The vascular grafts market consists of sales of polytetrafluoroethylene (Teflon), polyethylene terephthalate (Dacron), or a different person's vein (allograft). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vascular grafts market is segmented - 1) By Product: Hemodialysis Access Graft, Endovascular Stent Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft 2) By Raw Material: Polyester Grafts, ePTFE, Polyurethane Grafts, Biosynthetic Grafts 3) By Application: Coronary Artery Disease, Aneurysm, Vascular Occlusion, Renal Failure 4) By End-User: Hospitals, Ambulatory Surgical Centers

Intracranial stents are tubular device that is placed inside the blood vessel, canal, or duct. They are used for intracranial stenosis and brain aneurysms to open the blocked arteries. The main types of intracranial stents are self-expanding stents, balloon expanding stents, and stent-assisted coil embolization. A self-expanding stent expands on its own after being inserted into the lumen it is meant to occupy, such as a blood vessel, tube, or organ. Balloon expanding stents also known as balloon-expandable stents have higher radial stiffness and more accurate placement and are designed to treat restenosis in the iliac artery by opening clogged arteries and restoring blood flow. Stent-assisted coil embolization helps stabilize the coils within the aneurysm and provide a buttress that allows for coil deposition while preventing coil haerniation into the parent vessel lumen. The various indications of diseases include brain aneurysm, intracranial stenosis and are implemented in various sectors such as hospitals, ambulatory surgery centers, and others. The intracranial stents market research report is one of a series of new reports from The Business Research Company that provides intracranial stents market statistics, including intracranial stents industry global market size, regional shares, competitors with intracranial stents market share, detailed intracranial stents market segments, market trends and opportunities, and any further data you may need to thrive in the intracranial stents industry. This intracranial stents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global intracranial stents market size grew from $0.36 billion in 2022 to $0.43 billion in 2023 at a compound annual growth rate (CAGR) of 18.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intracranial stents market size is expected to grow to $0.73 billion in 2027 at a CAGR of 14.2%. The increase in incidence of a brain aneurysm is expected to propel the growth of the intracranial stents market in the coming years. A brain aneurysm is the development of a bulge in the blood vessels of the brain. This bulge may rupture or burst and can cause brain hemorrhage, which may lead to the death of the patient. Intracranial vessel stenting (IVS) is a minimally invasive treatment for treating serious cerebral artery stenosis. The weakening of the arteries that deliver blood to the brain is known as cerebral artery stenosis. According to the brain aneurysm foundation, by 2020, an expected 6.5 million people in the USA are suffering from an unruptured brain aneurysm, accounting for about one in every 50 people. Additionally, a brain aneurysm causes around 500,000 deaths globally every year and is more common among women. Thus, the increasing incidence of a brain aneurysm will drive the intracranial stents market growth. The introduction of flow diversion technology to the field of neurointervention has revolutionized the treatment of intracranial aneurysms which is a key trend gaining popularity in the intracranial stents market. Flow diversion is an endovascular procedure in which a device is inserted in the parent blood vessel to move blood flow away from the aneurysm rather than around the aneurysm sac. For instance, in March 2020, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) developed an innovative intracranial flow diverter stent for brain aneurysms treatment. Intracranial flow diverters have the benefit of becoming adaptable and flexible to the vessel's shape and direction and also helps the vessel wall recover by relieving it of the continuous burden of blood flow. It is entitled as Chitra flow diverter, the device is ready for transfer and further testing in animals to be followed by human trials. In January 2021, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institute of the Department of Science & Technology (DST), Govt of India, under the Technical Research Centre (TRC), announced that it has entered into Technology Transfer Agreements with Biorad Medisys, for two biomedical implant devices namely an Atrial Septal Defect Occluder and an Intracranial Flow Diverter Stents developed by the institute in collaboration with National Aerospace Laboratories, Bangalore (CSIR-NAL)using superelastic NiTiNOL alloys. Biorad Medisys is an India-based company that manufactures various implants and surgical devices. Major players in the intracranial stents market are Medtronic, Balt, Stryker Corporation, MicroPort Scientific Corporation, Boston Scientific Corporation, Acandis GmbH, Admedes Schuessler GmbH, MicroVention (Terumo), and Phenox. North America was the largest region in the intracranial stents market in 2022. Asia-Pacific is expected to be the fastest region in the intracranial stents market during the forecast period. The regions covered in the intracranial stents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the intracranial stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The intracranial stents market consists of sales of Neuroform stents, Solitaire, Enterprise, and Leo plus, and Wingspan stent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intracranial stents market is segmented - 1) By Type: Self Expanding Stents, Balloon Expanding Stents, Stent-Assisted Coil Embolization 2) By Disease Indication: Brain Aneurysm, Intracranial Stenosis 3) By End-User: Hospitals, Ambulatory Surgery Centers, Other End-Users

Cardiovascular devices are used to monitor and control the irregular heartbeats and heart rhythm disorders. The main types in the cardiovascular devices market are cardiovascular surgery devices and equipment, cardiac rhythm management (CRM) devices and equipment, interventional cardiology devices and equipment, defibrillator devices and equipment, peripheral vascular devices and equipment, prosthetic heart valve devices and equipment, electrophysiology devices and equipment, and cardiac assist devices and equipment. Defibrillators are devices that restore the normal heartbeat by sending an electric pulse or shock to the heart. They are used to prevent or correct an arrhythmia, a heartbeat that is uneven or slow or fast. The type of expenditure is public, or private. The products used are instruments/equipment, and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The cardiovascular devices market research report is one of a series of new reports from The Business Research Company that provides cardiovascular devices market statistics, including cardiovascular devices industry global market size, regional shares, competitors with a cardiovascular devices market share, detailed cardiovascular devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular devices industry. This cardiovascular devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cardiovascular devices market grew from $59.55 billion in 2022 to $64.39 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular devices market is expected to grow to $83.35 billion in 2027 at a CAGR of 6.7%. Leadless pacemakers are being used for certain medical conditions such as slow heart rate (bradycardia), as they provide a less-invasive alternative to conventional pacemakers. A leadless pacemaker is a self-contained device that is inserted in the right ventricle of the heart without incisional access, leads, or a surgical pocket. Furthermore, the medical procedure for a leadless pacemaker can be performed in under 30 minutes, with few postprocedural restrictions. These devices are gaining popularity as they eliminate complications related to lead placement which includes cardiac perforation, pneumothorax, and lead dislodgement. Major companies manufacturing leadless pacemakers are Medtronic and Abbott. Major companies in the cardiovascular devices market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc., and Becton Dickinson. North America was the largest region in the global cardiovascular devices market in 2022. Western Europe was the second largest region in the global cardiovascular devices market. Africa. was the smallest region in the global cardiovascular devices market. The regions covered in the cardiovascular devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cardiovascular devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The cardiovascular devices market consists of sales of biventricular devices, and implantable cardiac loop recorders that are used for monitoring and treatment of cardiovascular disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular devices market is segmented - 1) By Type: Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Cardiac assist devices and equipment are electromechanical devices that assist in pumping blood from the heart to the rest of the body. These devices are used either to partially or completely replace the function of a failing heart. The main types of cardiac assist devices and equipment are ventricular assist devices, intra-aortic balloon pumps, and the total artificial heart. Ventricular assist devices are electromechanical devices used to help with cardiac circulation. The various types of modalities are transcutaneous and implantable. These are used in hospital pharmacies, ambulatory surgical centres, and emergency services. The cardiac assist devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac assist devices and equipment market statistics, including cardiac assist devices and equipment industry global market size, regional shares, competitors with a cardiac assist devices and equipment market share, detailed cardiac assist devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac assist devices and equipment industry. This cardiac assist devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac assist devices and equipment market size will grow from $2.15 billion in 2022 to $2.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac assist devices and equipment market size is expected to grow to $3.51 billion in 2027 at a CAGR of 9.9%. A rise in the prevalence of cardiovascular diseases increases the demand for cardiac assist devices and equipment in developed and developing economies. The increasing need for diagnosis, monitoring, early-stage treatment, and prevention of these life-threatening diseases, increase the demand for cardiac assist devices. According to the American Heart Association, by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. According to the Centers for Disease Control and Prevention, anout 697,000 people died from heart diseases in 2020 which was almost 1 in every 5 deaths. Risks associated with the implantation of cardiac assist devices into the human body acts as a major restraint for the growth of this market. Risks associated with device implantation include respiratory failure, blood clot formation, occurrences of stroke, and the risk of device failure leading to a heart attack are some major reasons due to which people are hesitant to adopt cardiac assist devices, thus the demand from end-users of cardiac assist devices remains restrained, therefore limiting the growth prospects of the market. The infection rate of cardiac implantable electronic devices is 1.7% initially after implantation, whereas after 2years the infection rate is 9.5%, increasing the risk factor. The rising number of device replacements results in complex procedures, considerable risks with an increase in infection rates. Device miniaturization is becoming popular in the cardiac assist devices and equipment market. The concept of minimizing the size of the cardiac assist devices enhances device implantation, provides potentially shorter hospital stay through the use of less invasive surgery such as 'Thoracotomy'. Cardiac assist device miniaturization acts as a replacement to heart transplantation as destination therapy, due to lack of heart donors. For instance, Heartware Ltd. is increasingly investing in the Heartware's device miniaturization program, aiming to reduce the weight, size, and energy consumption of the device. Furthermore, the United Kingdom National Health Service has invested in a Bridge to Transplant program (BTT) where the performance of two minimally invasive cardiac assist devices was compared, out of which the best one was found based on better clinical outcome and more cost-effectiveness due to its miniaturized design. In June 2021, Medtronic PLC., an Irish medical device company, stopped the sale and distribution of the HeartWare Ventricular Assist Devices system due to the risk of mortality and neurological adverse events due to the use of the device and malfunctioning in the starting of the device. Major players in the cardiac assist devices and equipment market are Abbot Laboratories, Berlin Heart GmbH, Abiomed Inc., Bivacor Pvt Ltd., Calon Cardio - Technology Ltd., Cardiobridge GmbH, Balton Sp. Z O.O, Cardiac Assist Inc., Braile Biomedica Ltd., and Circulate Inc. North America was the largest region in global cardiac assist devices and equipment market in 2022. Western Europe was the second-largest region in cardiac assist devices and equipment market. The regions covered in global cardiac assist devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac assist devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The cardiac assist devices and equipment market consist of sales of ventricular assist devices (LVAD), intra-aortic balloon pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac assist devices and equipment market is segmented - 1) By Type: Ventricular Assist Devices (LVAD), Intra-Aotic Baloon Pumps, Total Artificial Heart 2) By Application: Hospital Pharmacies, Ambulatory Surgical Centres, Emergency Services 3) By Modality: Transcutaneous, Implantable